UNASSIGNED: @entity1149 ( @entity1149 ) remains the most common cause of @entity5 worldwide. @entity1 presenting with advanced-stage @entity1149 have poor prognosis, while metastatic spread accounts for >70  % of @entity1 's deaths. The major advances in the treatment of @entity2 have brought only minor improvements in survival; therefore, novel strategic treatment approaches are urgently needed. Accumulating data allocate a central role for the @entity5 microenvironment including mesenchymal stem cells (MSCs) in acquisition of drug resistance and disease relapse. Furthermore, studies indicate that translation initiation factors are over expressed in @entity1149 and negatively impact its prognosis. Importantly, translation initiation is highly modulated by microenvironmental cues. Therefore, we decided to examine the effect of bone marrow MSCs (BM-MSCs) from normal donors on @entity1149 cell lines with special emphasis on translation initiation mechanism in the crosstalk. We cultured @entity1149 cell lines with BM-MSC conditioned media (i.e., secretome) and showed deleterious effects on the cells' proliferation, viability, @entity204 , and migration. We also demonstrated reduced levels of translation initiation factors implicated in @entity5 progression [ @entity4043 ( @entity4043 ) and @entity5290 ( @entity5290 )], their targets, and regulators. Finally, we outlined a mechanism by which BM-MSCs' secretome affected @entity1149 's mitogen-activated protein kinase (MAPK) signaling pathway, downregulated the cell migration, and diminished translation initiation factors' levels. Taken together, our study demonstrates that there is direct dialogue between the BM-MSCs' secretome and @entity1149 cells that manipulates translation initiation and critically affects cell fate. We suggest that therapeutic approach that will sabotage this dialogue, especially in the BM microenvironment, may diminish @entity2 metastatic spread and morbidity and improve the @entity1 's life quality.

Secretome of @entity1 bone marrow mesenchymal stem cells: an emerging XXXX progression and mechanisms of translation initiation.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related death', 'cancer'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'Non-small cell lung cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity5290 :: ('1981', 'Gene') :: ['eIF4GI', 'eukaryotic translation initiation factor 4GI'] @entity4043 :: ('1977', 'Gene') :: ['eIF4E', 'eukaryotic translation initiation factor 4E'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity2 :: (MESH:D008175,Disease) :: ['player in lung cancer']
